Healthcare Resource Consumption and Related Costs in Patients Under Antiretroviral Therapies: Findings From Real-World Data in Italy
Author(s)
Perrone V1, Dovizio M2, Sangiorgi D2, Andretta M3, Bartolini F4, Cavaliere A5, Ciaccia A6, Chinellato A7, Costantini A8, Dell'Orco S9, Ferrante F10, Gentile S11, Lavalle A11, Moscogiuri R12, Mosele E13, Procacci C14, Re D15, Santoleri F8, Roccia A16, Maggiolo F17, Degli Esposti L2
1CliCon S.r.l. Società Benefit Health, Economics & Outcomes Research, Bologna, BO, Italy, 2CliCon S.r.l. Società Benefit Health, Economics & Outcomes Research, Bologna, Italy, 3Azienda ULSS 8 Berica, Vicenza, Italy, 4USL Umbria 2, Terni, Italy, 5ASL Viterbo, Viterbo, Italy, 6Servizio Farmaceutico Territoriale ASL Foggia, Foggia, Italy, 7Azienda ULSS 3 Serenissima, Mestre (VE), Italy, 8ASL Pescara, Pescara, Italy, 9ASL Roma 6, Albano Laziale, Italy, 10ASL Frosinone, Frosinone, Italy, 11Direzione Generale per la Salute Regione Molise, Campobasso, Italy, 12ASL Taranto, Taranto, Italy, 13UOC Assistenza Farmaceutica Territoriale Azienda ULSS 7 Pedemontana, Bassano del Grappa (VI), Italy, 14Dipartimento Farmaceutico ASL BAT, Trani, Italy, 15ASL Teramo, Roseto degli Abruzzi, Italy, 16Gilead Sciences Srl, Milano, Italy, 17ASST Papa Giovanni XXIII, Bergamo, Italy
Presentation Documents
OBJECTIVES: Little is known about the healthcare resource consumptions and related costs in patients on antiretroviral therapy (ART), in the Italian setting.
METHODS: We performed a retrospective real-world analysis on administrative databases of Entities covering 5.5 millions health-assisted individuals, during 2015-2019. All adults taking Tenofovir Alafenamide(TAF)-based regimens were identified; the first TAF prescription was the index-date. Persistence on therapy was calculated as presence of ART during last trimester of each calendar year. Healthcare resource consumptions (mean±standard deviation) and direct costs (euro; €) related to ART, other-drugs (non-ART), HIV-related and other reasons-hospitalizations, laboratory tests/outpatient visits, were calculated over one-year follow-up. A generalized linear model (GLM) was applied to evaluate predictors of non-ART total costs.
RESULTS: 1,198 patients were identified. Across 2017-2019, we found a mean per patient number of 8.0±2.4 - 7.7±2.4 ART prescriptions, 4.4±5.0 - 3.4±4.0 non-ART prescriptions, 0.2±0.5 - 0.1±0.4 HIV-hospitalizations, and 8.5±7.6 - 5.9±7.6 test/visits prescriptions. Mean annual direct costs averaged 15,493€ (2017), 12,060€ (2018), and 10,216€ (2019). ART-related cost was the most relevant item with 10,685€, 9,474€, and 8,017€, for 2017, 2018, and 2019, respectively. Persistent patients were characterized by lower total costs versus non-persistent (11,106€ vs 12,380€, P=0.005), mostly due to the reduction of HIV-hospitalizations, non-ART drugs and test/visits costs. The GLM model showed that non-ART costs increased with older age (patients aging 35 years as reference), +1,360€ in those ranging 51-65 years (P<0.001) and +2,264€ in >65, (P=0.079) and to the Charlson Comorbidity Index (CCI) (+1,736€ for CCI unit increment, P=0.027).
CONCLUSIONS: This real-world analysis in TAF-treated patients showed that healthcare total costs were mainly driven by ART-related costs, which represent almost 70% of the total expenditure. TAF persistence was associated with cost saving, due to a reduction of total healthcare cost related to HIV-hospitalizations, non-ART drug prescriptions, outpatients visits and specialist services.
Conference/Value in Health Info
Value in Health, Volume 25, Issue 12S (December 2022)
Code
EE366
Topic
Economic Evaluation
Disease
SDC: Infectious Disease (non-vaccine), STA: Drugs